Marine Drugs (Jan 2022)

Bacillimidazoles A−F, Imidazolium-Containing Compounds Isolated from a Marine <i>Bacillus</i>

  • Jia-Xuan Yan,
  • Qihao Wu,
  • Eric J. N. Helfrich,
  • Marc G. Chevrette,
  • Doug R. Braun,
  • Heino Heyman,
  • Gene E. Ananiev,
  • Scott R. Rajski,
  • Cameron R. Currie,
  • Jon Clardy,
  • Tim S. Bugni

DOI
https://doi.org/10.3390/md20010043
Journal volume & issue
Vol. 20, no. 1
p. 43

Abstract

Read online

Chemical investigations of a marine sponge-associated Bacillus revealed six new imidazolium-containing compounds, bacillimidazoles A–F (1–6). Previous reports of related imidazolium-containing natural products are rare. Initially unveiled by timsTOF (trapped ion mobility spectrometry) MS data, extensive HRMS and 1D and 2D NMR analyses enabled the structural elucidation of 1–6. In addition, a plausible biosynthetic pathway to bacillimidazoles is proposed based on isotopic labeling experiments and invokes the highly reactive glycolytic adduct 2,3-butanedione. Combined, the results of structure elucidation efforts, isotopic labeling studies and bioinformatics suggest that 1–6 result from a fascinating intersection of primary and secondary metabolic pathways in Bacillus sp. WMMC1349. Antimicrobial assays revealed that, of 1–6, only compound six displayed discernible antibacterial activity, despite the close structural similarities shared by all six natural products.

Keywords